Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population

Shunan Qi, Joachim Yahalom, Meier Hsu, Monica Chelius, Matthew A Lunning, Alison Moskowitz, Steven Horwitz

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Extra-nodal NK/T-cell lymphoma, nasal type (EN-NK/TCL-NT), is rare in the Western world. We launched the current single-institutional retrospective study with Institutional Review Board approval to better understand the disease. 43 EN-NK/TCL-NT patients treated from 1996 to 2014 were analyzed, including 10 (23%) Asians and 33 (76%) non-Asians. 19/26 (73%) early-stage patients received short-course chemotherapy followed by radiotherapy. 14/17 (82%) advanced-stage patients received primary chemotherapy. Complete response rate was significantly higher in the modified-SMILE group than the accelerated-CHOP group (80% vs. 30%, p = 0.015). The 2-year overall survival (OS) and progression-free survival (PFS) were 60% and 40%, respectively. Early-stage disease had significantly higher 2-year OS (87% vs. 21%) and PFS (56% vs.18%) than advanced-stage (p 

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - May 16 2016
Externally publishedYes

Fingerprint

T-Cell Lymphoma
Nose
Natural Killer Cells
Disease-Free Survival
Population
Drug Therapy
Western World
Survival
Research Ethics Committees
Radiotherapy
Therapeutics
Retrospective Studies

Keywords

  • Drug therapy
  • ethnology
  • extranodal NK-T-cell lymphomas
  • radiotherapy
  • SMILE

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population. / Qi, Shunan; Yahalom, Joachim; Hsu, Meier; Chelius, Monica; Lunning, Matthew A; Moskowitz, Alison; Horwitz, Steven.

In: Leukemia and Lymphoma, 16.05.2016, p. 1-9.

Research output: Contribution to journalArticle

Qi, Shunan ; Yahalom, Joachim ; Hsu, Meier ; Chelius, Monica ; Lunning, Matthew A ; Moskowitz, Alison ; Horwitz, Steven. / Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population. In: Leukemia and Lymphoma. 2016 ; pp. 1-9.
@article{8417489a7043457a98a09d1b15bb44a5,
title = "Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population",
abstract = "Extra-nodal NK/T-cell lymphoma, nasal type (EN-NK/TCL-NT), is rare in the Western world. We launched the current single-institutional retrospective study with Institutional Review Board approval to better understand the disease. 43 EN-NK/TCL-NT patients treated from 1996 to 2014 were analyzed, including 10 (23{\%}) Asians and 33 (76{\%}) non-Asians. 19/26 (73{\%}) early-stage patients received short-course chemotherapy followed by radiotherapy. 14/17 (82{\%}) advanced-stage patients received primary chemotherapy. Complete response rate was significantly higher in the modified-SMILE group than the accelerated-CHOP group (80{\%} vs. 30{\%}, p = 0.015). The 2-year overall survival (OS) and progression-free survival (PFS) were 60{\%} and 40{\%}, respectively. Early-stage disease had significantly higher 2-year OS (87{\%} vs. 21{\%}) and PFS (56{\%} vs.18{\%}) than advanced-stage (p ",
keywords = "Drug therapy, ethnology, extranodal NK-T-cell lymphomas, radiotherapy, SMILE",
author = "Shunan Qi and Joachim Yahalom and Meier Hsu and Monica Chelius and Lunning, {Matthew A} and Alison Moskowitz and Steven Horwitz",
year = "2016",
month = "5",
day = "16",
doi = "10.1080/10428194.2016.1180689",
language = "English (US)",
pages = "1--9",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population

AU - Qi, Shunan

AU - Yahalom, Joachim

AU - Hsu, Meier

AU - Chelius, Monica

AU - Lunning, Matthew A

AU - Moskowitz, Alison

AU - Horwitz, Steven

PY - 2016/5/16

Y1 - 2016/5/16

N2 - Extra-nodal NK/T-cell lymphoma, nasal type (EN-NK/TCL-NT), is rare in the Western world. We launched the current single-institutional retrospective study with Institutional Review Board approval to better understand the disease. 43 EN-NK/TCL-NT patients treated from 1996 to 2014 were analyzed, including 10 (23%) Asians and 33 (76%) non-Asians. 19/26 (73%) early-stage patients received short-course chemotherapy followed by radiotherapy. 14/17 (82%) advanced-stage patients received primary chemotherapy. Complete response rate was significantly higher in the modified-SMILE group than the accelerated-CHOP group (80% vs. 30%, p = 0.015). The 2-year overall survival (OS) and progression-free survival (PFS) were 60% and 40%, respectively. Early-stage disease had significantly higher 2-year OS (87% vs. 21%) and PFS (56% vs.18%) than advanced-stage (p 

AB - Extra-nodal NK/T-cell lymphoma, nasal type (EN-NK/TCL-NT), is rare in the Western world. We launched the current single-institutional retrospective study with Institutional Review Board approval to better understand the disease. 43 EN-NK/TCL-NT patients treated from 1996 to 2014 were analyzed, including 10 (23%) Asians and 33 (76%) non-Asians. 19/26 (73%) early-stage patients received short-course chemotherapy followed by radiotherapy. 14/17 (82%) advanced-stage patients received primary chemotherapy. Complete response rate was significantly higher in the modified-SMILE group than the accelerated-CHOP group (80% vs. 30%, p = 0.015). The 2-year overall survival (OS) and progression-free survival (PFS) were 60% and 40%, respectively. Early-stage disease had significantly higher 2-year OS (87% vs. 21%) and PFS (56% vs.18%) than advanced-stage (p 

KW - Drug therapy

KW - ethnology

KW - extranodal NK-T-cell lymphomas

KW - radiotherapy

KW - SMILE

UR - http://www.scopus.com/inward/record.url?scp=84969228136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969228136&partnerID=8YFLogxK

U2 - 10.1080/10428194.2016.1180689

DO - 10.1080/10428194.2016.1180689

M3 - Article

SP - 1

EP - 9

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -